Beird, Hannah C. http://orcid.org/0000-0002-5078-534X
Khan, Maliha
Wang, Feng
Alfayez, Mansour
Cai, Tianyu
Zhao, Li
Khoury, Joseph http://orcid.org/0000-0003-2621-3584
Futreal, P. Andrew
Konopleva, Marina
Pemmaraju, Naveen
Funding for this research was provided by:
UT | University of Texas MD Anderson Cancer Center (CA016672)
Article History
Received: 8 July 2019
Revised: 6 November 2019
Accepted: 11 November 2019
First Online: 6 December 2019
Conflict of interest
: M. Konopleva receives consulting/honorarium from: AbbVie, Genentech, F. Hoffman La-Roche, Stemline Therapeutics, Amgen, Forty-Seven. M. Konopleva receives research funding/clinical trials support from AbbVie, Genentech, F. Hoffman La-Roche, Eli Lilly, Cellectis, Calithera, Ablynx, Stemline Therapeutics, Agios, Ascentage. M. Konopleva holds stock options/royalties in Reata Pharmaceutical. For N.P.: research funding and honorarium were given by ThermoFisher, Stemline Therapeutics, and Cellectis. N.P. receives consulting/honorarium from:AbbVie; Celgene; Stemline; Incyte; Novartis; MustangBio; Roche Diagnostics, LFB; research funding/clinical trials support from:Stemline; Novartis; AbbVie; Samus; Cellectis; Plexxikon; Daiichi-Sankyo; Affymetrix; grants/funding from:Affymetrix, SagerStrong Foundation.